A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2, PHASE3

מצבים רפואיים

Metastatic Uveal Melanoma

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • HonorHealth Research Insisute, Scottsdale, Arizona, United States

    Contact: Study coordinator (Justin Moser, MD)
  • UC San Diego Moores Cancer Center, La Jolla, California, United States

    Contact: Study coordinator (Gregory Daniels, MD)
  • The Angeles Clinic and Research Institute, Los Angeles, California, United States

    Contact: Study coordinator (Inderjit Mehmi, MD)
  • University of California Los Angeles, Los Angeles, California, United States

    Contact: Study coordinator (Bartosz Chmielowski, MD)
  • Stanford Cancer Institute, Palo Alto, California, United States

    Contact: Study coordinator (Allison Betof Warner, MD)
  • University of Colorado Hospital - Anschutz Cancer Pavilion(ACP), Aurora, Colorado, United States

    Contact: Study coordinator (Sapna Pradyuman Patel, MD)
  • The Melanoma & Skin Cancer Institute, Englewood, Colorado, United States

    Contact: Study coordinator (Ryan Weight, DO, MS)
  • Georgetown University Medical Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Suthee Rapisuwon, MD)
  • Mayo Clinic - Jacksonville FL, Jacksonville, Florida, United States

    Contact: Study coordinator (Roxana S. Dronca, MD)
  • Sylvester Comprehensive Cancer Center, Miami, Florida, United States

    Contact: Study coordinator (Leonel Fernando Hernandez Aya, MD)
  • Emory Winship Cancer Institute, Atlanta, Georgia, United States

    Contact: Study coordinator (Michael Lowe, MD)
  • Northwestern Memorial Hospital, Chicago, Illinois, United States

    Contact: Study coordinator (Sunandana Chandra, MD, MS)
  • University of Chicago Medical Center, Chicago, Illinois, United States

    Contact: Study coordinator (Daniel Olson, MD)
  • University of Iowa, Iowa City, Iowa, United States

    Contact: Study coordinator (Asad Javed, MD)
  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Kamaneh Montazeri, MD)
  • Mayo Clinic Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Arkadiusz Z. Dudek, MD)
  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Alexander Shoushtari, MD)
  • Duke University Medical Center, Durham, North Carolina, United States

    Contact: Study coordinator (April Salama, MD)
  • The Ohio State University, Columbus, Ohio, United States

    Contact: Study coordinator (Richard Wu, MD, PhD)
  • Thomas Jefferson University, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Marlana Orloff, MD)
  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Diwakar Davar, MD)
  • The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee, United States

    Contact: Study coordinator (Arnel M. Pallera, MD)
  • University of Tennessee Medical Center, Knoxville, Tennessee, United States

    Contact: Study coordinator (Timothy Panella, MD)
  • Sarah Cannon Research Institute, Nashville, Tennessee, United States

    Contact: Study coordinator (Meredith Ann McKean, MD, MPH)
  • Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic), Nashville, Tennessee, United States

    Contact: Study coordinator (Douglas B. Johnson, MD)
  • UT Southwestern Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Sanjay Chandrasekaran, MD)
  • The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Alexandra Ikeguchi, MD)
  • Fred Hutchinson Cancer Center, Seattle, Washington, United States

    Contact: Study coordinator (Natalie Miller, MD, PhD)
  • University Of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States

    Contact: Study coordinator (Vincent Ma, MD)
  • Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia

    Contact: Study coordinator (Georgina Long, MD)
  • Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    Contact: Study coordinator (Damien Kee, MD)
  • The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Merseyside, United Kingdom

    Contact: Study coordinator (Joseph Sacco)
  • The Royal Marsden NHS Foundation Trust, London, United Kingdom

    Contact: Study coordinator (James Larkin)
מובילי המחקר
  • Rahul Marpadga, MD MPH

    Study Director

    Replimune, Inc.